Background: Provider-initiated HIV counseling and testing (PIHIVCT) is an important intervention that improves the access to care to HIV-infected patients and subsequently contributes to the success of national HIV/AIDS control efforts. However, in Thailand, the cost-effectiveness of this program is unknown. Objective: Determine the incremental cost-effectiveness ratios (ICER) in terms of Thai Baht per Quality Adjusted Life Year (QALY) of PIHIVCT for outpatient department (OPD) patients in community hospitals of Thailand compared with the current practice. Methods: A model-based health economic evaluation study was conducted based on results from cluster randomized controlled trials in 16 community hospitals of Thailand. The Markov model and the probabilistic sensitivity analysis were used. One-thousand two-hundred seventy-seven HIV-infected patients completed questionnaires on their household expenditure and quality of life using the visual analog scale. Results: In social perspectives, the PIHIVCT program increased a patient’s life span by 5.18 days or 4.15 qualityadjusted days per OPD case and the ICER was 63,588 Baht per QALY gained. The subgroup analysis showed that the PIHIVCT program would be cost-effective for cases younger than 50 years if the ceiling threshold of willing to pay equaled the per capita Gross Domestic Product (GDP). However, this intervention would be cost-effective for all cases of 13-64 year old if the ceiling threshold equaled three times of GDP. Conclusion: The provider-initiated HIV counseling and testing program for OPD patients is more cost-effective than the current practice and should be implemented in health care setting in Thailand.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. UNAIDS. 2008 Report on the global AIDS epidemic. Geneva: WHO Library Cataloguing-in-Publication Data 2008.
2. Pongpun S Poolkasorn S Kaesaudomthub V Pliput T. Situation of HIV infection in Thailand 2007. Nonthaburi: Bureau of Epidemiology Department of Disease Control Ministry of Public Health; 2008.
3. Bureau of Epidemiology Department of Disease Control Ministry of Public Health of Thailand. HIV prevention and implementation in men who have sex with men. Nonthaburi: Printing House of the War Veterans Organization of Thailand; 2008.
4. Chasombat S McConnell MS Siangphoe U Yuktanont P Jirawattanapisal T Fox K et al. National expansion of antiretroviral treatment in Thailand 2000-2007: program scale-up and patient outcomes. J Acquir Immune Defic Syndr. 2009; 50:506-12.
5. The Thai Working Group on HIV/AIDS Projections. The Asian epidemic model (AEM) projections for HIV/AIDS in Thailand: 2005-2025. Family Health International (FHI) and Bureau of AIDS TB and STIs Department of Disease Control Ministry of Public Health Thailand. 2008.
6. Revenga A Over M Masaki E Peerapatanapokin W Gold J Tangcharoensathien V et al. The economics of effective AIDS treatment: evaluating policy options for Thailand. Washington DC: The World Bank 2006.
7. Manosuthi W Chaovavanich A Tansuphaswadikul S Prasithsirikul W Inthong Y Chottanapund S et al. Incidence and risk factors of major opportunistic infections after initiation of antiretroviral therapy among advanced HIV-infected patients in a resourcelimited setting. J Infect. 2007; 55:464-9.
8. Ormaasen V Sandvik L Dudman SG Bruun JN. HIV related and non-HIV related mortality before and after the introduction of highly active antiretroviral therapy (HAART) in Norway compared to the general population. Scand J Infect Dis. 2007; 39:51-7.
9. Garcia F de Lazzari E Plana M Castro P Mestre G Nomdedeu M et al. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr. 2004; 36:702-13.
10. Egger M May M Chene G Phillips AN Ledergerber B Dabis F et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002; 360:119-29.
11. Kitahata MM Gange SJ Abraham AG Merriman B Saag MS Justice AC et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009; 360:1815-26.
12. Lapadula G Torti C Maggiolo F Casari S Suter F Minoli L et al. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3. Antivir Ther. 2007; 12:941-7.
13. Center for Disease Control and Prevention. Recommendations for HIV testing services for inpatients and outpatients in acute-care hospital settings. MMWR (Mortality Morbidity Weekly Report) Recomm Rep. 1993; 42:1-6.
14. Center for Disease Control and Prevention. Revised recommendations for HIV screening of pregnant women. MMWR (Mortality Morbidity Weekly Report). Recomm Rep. 2001; 50:63-85.
15. Walensky RP Weinstein MC Kimmel AD Seage Iii GR Losina E Sax PE et al. Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. Am J Med. 2005; 118: 292-300.
16. Paltiel AD Walensky RP Schackman BR Seage GR 3rd Mercincavage LM Weinstein MC et al. Expanded HIV screening in the United States: effect on clinical outcomes HIV transmission and costs. Ann Intern Med. 2006; 145:797-806.
17. Paltiel AD Weinstein MC Kimmel AD Seage GR 3rd Losina E Zhang H et al. Expanded screening for HIV in the United States-an analysis of costeffectiveness. N Engl J Med. 2005; 352:586-95.
18. Sanders GD Bayoumi AM Sundaram V Bilir SP Neukermans CP Rydzak CE et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005; 352:570-85.
19. Resch S Altice FL Paltiel AD. Cost-effectiveness of HIV screening for incarcerated pregnant women. J Acquir Immune Defic Syndr. 2005; 38:163-73.
20. Center for Disease Control and Prevention. Revised recommendations for HIV testing of adult adolescents and pregnant woman in health-care setting. MMWR (Mortality Morbidity Weekly Report) Recomm Rep. 2006; 55:1-17.
21. WHO/UNAIDS. Guidance on provider-initiated HIV testing and counselling in health facilities. Geneva:WHO press 2007.
22. Teerawattananon Y Leelukkanaveera Y Hanvoravongchai P Thavorncharoensap M Ingsrisawang L Tantivess S et al. Provider-initiated HIV/AIDS counseling and testing at healthcare facilities in Thailand: cluster-randomisation trial. J Develop Effect. 2009; 1:450-69.
23. Fox-Rushby J Cairns J. Economic Evaluation. Berkshire:Open University Press; 2008.
24. Fylkesnes K Siziya S. A randomized trial on acceptability of voluntary HIV counseling and testing. Trop Med Int Health. 2004; 9:566-72.
25. Nuwaha F Kabatesi D Muganwa M Whalen CC. Factors influencing acceptability of voluntary counselling and testing for HIV in Bushenyi district of Uganda. East Afr Med J. 2002; 79:626-32.
26. Thielman NM Chu HY Ostermann J Itemba DK Mgonja A Mtweve S et al. Cost-effectiveness of free HIV voluntary counseling and testing through a community-based AIDS service organization in Northern Tanzania. Am J Public Health. 2006; 96:114-9.
27. Walensky RP Weinstein MC Smith HE Freedberg KA Paltiel AD. Optimal allocation of testing dollars: the example of HIV counseling testing and referral. Med Decis Making. 2005; 25:321-9.